Key Highlights
- Cleveland Diagnostics appoints Dara Grantham Wright to Board of Directors.
- Wright brings extensive experience in life science research and clinical diagnostics.
- She has held senior executive roles at Bio-Rad, Thermo Fisher Scientific, and Becton Dickinson.
- Wright will support the expansion and commercialization of IsoPSA® and IsoClear™ platforms.
- Appointment follows Cleveland Diagnostics’ successful $75M growth equity financing.
Source: Business Wire
Notable Quotes
- “I am honored to join the Board of Directors at Cleveland Diagnostics. I look forward to supporting their mission of expanding access to leading-edge diagnostic tests to significantly enhance early cancer detection.” — Dara Grantham Wright, New Independent Director at Cleveland Diagnostics
- “I am very pleased to have Dara join our Board. Dara’s extensive hands-on experience in scaling up both small and large companies in the diagnostics space will be incredibly valuable as Cleveland Diagnostics navigates commercializing our unique, highly accurate cancer tests – especially as we explore new therapeutic areas with our proprietary platform, IsoClear™. I am eager to have Dara contribute to our future and look forward to working closely with her.” — Arnon Chait, PhD, President and CEO at Cleveland Diagnostics
SoHC's Take
The appointment of Dara Grantham Wright to Cleveland Diagnostics’ Board of Directors is a strategic move that underscores the company’s commitment to scaling its innovative cancer diagnostics solutions. Wright’s robust background in life sciences and clinical diagnostics, coupled with her leadership experience at prominent industry players like Bio-Rad and Thermo Fisher Scientific, positions her as a valuable asset in driving the commercialization of Cleveland Diagnostics’ IsoPSA® test and the development of the IsoClear™ platform. Her expertise will be crucial as the company leverages its recent $75M financing to expand its product offerings and enhance early cancer detection capabilities. This appointment not only strengthens the Board but also signifies Cleveland Diagnostics’ forward-thinking approach to transforming cancer diagnostics.
